An observational study in Newly Diagnosed, Treatment-naïve Prostate Cancer, sponsored by Xijing Hospital. Recruiting at 9 sites in China. Open to male participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Xijing Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Neoplasms by Xijing Hospital — 10 open to participants now, 10 under way, none of them phase 3. Prostatic Neoplasms · Xijing Hospital.
Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 6th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →10 of the 10 studies in Prostatic Neoplasms by Xijing Hospital are open now, in 2 countries. Recruiting first, the newest first:
Xijing Hospital · Sites in China
Ages 18+ · Men only
Xijing Hospital · Sites in China
Ages 18–75 · Healthy volunteers
Xijing Hospital · Sites in China
Ages 18–75 · Men only
Xijing Hospital · Sites in China
Ages 40–90 · Men only · Healthy volunteers
Xijing Hospital · Sites in United States, China
Ages 18+ · Men only
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years to 100 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 200 across 1,312 observational studies indexed under Prostatic Neoplasms.
Median enrollment 190 across the 4 interventional studies, 1,000 across the 6 observational. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
4 of the studies in Prostatic Neoplasms by Xijing Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06604130Xijing HospitalPlasma Exosome RNA to Diagnose Prostate Cancer | 2026-12-31 |
| NCT07492927Xijing HospitalPlasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer | 2026-12-31 |
| NCT06914427Xijing HospitalPET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique | 2027-03-01 |
| NCT07553754Xijing HospitalPlasma Exosomal RNA Signature for Prostate Cancer Bone Metastasis | 2027-06-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Neoplasms by Xijing Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Brief Summary: Under the support of the PROMISE scoring criteria, PSMA PET has demonstrated significant prognostic value. However, previous studies on PSMA PET included patients with various stages of prostate cancer, and the mixture of different disease stages may compromise the accuracy of prognostic tools. This study aims to specifically investigate the prognostic value of initial staging PSMA PET for progression-free survival in patients with newly diagnosed, treatment-naïve prostate cancer, and to develop corresponding prognostic tools.
Need:
The prognostic value of initial staging with PSMA PET is needed for treatment management and study design.
Primary Outcome:
To assess the prognostic value of initial staging by PSMA PET: generate a prognostic tool (PSMA-VISION score) based on initial staging of PSMA PET to predict progression-free survival.
Secondary Outcomes:
To compare PSMA-VISION score with the other prognostic tools (such as NCCN, STARCAP, PPP nomogram, PPP2 nomogram, etc.) and to evaluate the prognostic value of initial staging by PSMA PET to predict overall survival (OS). The correlation with clinicopathological variables and prediction of early progression (Exploratory) was also investigated.
Inclusion:
Exclusion Criteria:
Background Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) has fundamentally transformed the staging paradigm for prostate cancer, demonstrating superior sensitivity and specificity compared to conventional imaging for the detection of metastatic disease . The Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria were established to standardize PSMA PET reporting, enabling reproducible and anatomically consistent disease characterization . Recent large-scale, international multi-centre studies have validated the robust prognostic value of PSMA-PET PROMISE (PPP) nomograms. These tools have shown superior accuracy in stratifying risk for overall survival across all disease stages when compared to established clinical risk tools such as the NCCN and EAU risk scores . The quantitative and visual PPP nomograms, incorporating parameters such as distant metastatic burden (M1a, M1b, M1c), total tumour volume, and PSMA expression score, have achieved C-indices of 0.77-0.80 for predicting overall survival, confirming the powerful prognostic information embedded within PSMA PET imaging .
Need While the prognostic utility of PSMA PET is established, previous studies, including the foundational PPP nomogram development, have largely enrolled cohorts comprising patients with mixed disease states-including those at initial staging, biochemical recurrence, and metastatic castration-resistant prostate cancer . This heterogeneity represents a significant confounder. The inclusion of patients with varying prior treatment exposures (e.g., post-radical prostatectomy, post-radiotherapy, post-systemic therapy) and at disparate points in their disease trajectory may obscure the true baseline prognostic power of the initial staging scan . A critical evidence gap remains regarding the specific prognostic value of the first, pre-treatment PSMA PET scan in a uniformly treatment-naïve population undergoing initial staging. Existing data on the direct correlation between baseline quantitative PSMA PET parameters and long-term outcomes like progression-free survival (PFS) in this specific, homogeneous cohort are lacking. As noted in recent literature, while PSMA PET provides unprecedented risk stratification, its direct impact on patient outcomes and the optimal integration of its quantitative metrics into prognostic tools for untreated patients require further prospective validation .
Aim / Objective
Primary Outcomes:
The primary aim of this study is to prospectively investigate the prognostic value of baseline staging PSMA PET for predicting progression-free survival (PFS) in patients with newly diagnosed, histologically confirmed, treatment-naïve prostate cancer. We will develop and validate a dedicated prognostic tool (nomogram or risk model) incorporating baseline PSMA PET parameters (e.g., SUVmax, lesion count, metastatic stage [miTNM]) alongside standard clinico-pathological variables to stratify patients by risk of disease progression.
Secondary Outcomes:
Inclusion:
Exclusion Criteria:
Statistical considerations:
This is an observational cohort study leveraging prospectively collected data from various centers. The sample size is determined by the availability of eligible patients meeting the inclusion criteria during the study period, with a planned enrollment of approximately 1000 patients.
Given the exploratory nature of this study and the absence of pre-specified effect sizes, a formal sample size calculation was not performed. However, with a minimum follow-up of 2 years for progression-free survival (PFS), we anticipate a sufficient number of PFS events to enable multivariable regression analyses. Based on the 10 events per variable (EPV) rule of thumb , this sample size will support the inclusion of 10 key predictor variables in the final model.
The prognostic value of baseline PSMA PET parameters (including PSMA-VISION score, miTNM stage, and SUV metrics) for PFS will be assessed using Cox proportional hazards regression models. Hazard ratios (HR) with 95% confidence intervals (CI) will be reported. The proportional hazards assumption will be tested using Schoenfeld residuals.
The predictive performance of the PSMA-VISION score will be evaluated using Harrell's C-index for time-to-event data. The C-index quantifies the model's ability to discriminate between patients with different PFS outcomes. To compare the prognostic performance of the PSMA-VISION score against established risk tools (NCCN risk categories, PPP nomogram), we will calculate the difference in C-indices with 95% CIs, using bootstrap resampling (1000 replicates) to account for over-optimism.
For the secondary endpoint comparing PSMA-VISION with other prognostic tools, time-dependent receiver operating characteristic (ROC) curve analysis will be performed, and the area under the curve (AUC) at 12 and 24 months will be calculated and compared using the method of DeLong et al.
As this is an open cohort study, continuous data accrual will improve the precision of prognostic estimates. All statistical tests will be two-sided, with p \< 0.05 considered statistically significant. Analyses will be performed using R software (version 4.x) with relevant packages (e.g., survival, timeROC, compareC).
Central Database:
Data will be stored centrally in a RedCap Database with 3-step authentication at the sponsor site.
Recurring Data Entry:
Data entry will be conducted repeatedly at about 3 to 6 month intervals.
Newly diagnosed, treatment-naïve prostate cancer patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
No.
Progression-Free Survival (PFS)
PFS is defined as the time from the date of baseline PSMA PET/CT to the date of first documented evidence of disease progression or death from any cause, whichever occurs first. Disease progression includes any of the following events: Biochemical recurrence (BCR): For patients without metastasis (M0) at baseline, defined per EAU/NCCN criteria as a PSA rise to ≥ 0.2 ng/mL (post-radical prostatectomy) and confirmed on a subsequent test, or a rise of ≥ 2 ng/mL above the nadir (post-radiotherapy). Locoregional progression: Imaging or pathologically confirmed local recurrence or regional lymph node metastasis. Distant metastasis: Imaging-confirmed new distant metastasis (M1a-c). Initiation of subsequent anticancer therapy: Start of a new line of treatment (e.g., ADT, chemotherapy, radiotherapy) due to disease progression.
Time frame: Up to 2 years
Overall survival
Time from PSMA-PET until death
Time frame: Up to 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Mar 2028, 24 months after the start.
Of 542 non-industry observational studies under Prostatic Neoplasms, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 162. This study's planned 24 months is below that.
Counting every sponsor, half of 651 studies reached it within 60 months; a quarter within 28 and three quarters within 141.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.